Other languages Nuvectis Pharma, Inc.

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 10/06/2024 BST			5-day change	1st Jan Change
6.53 ^USD	+3.00%		-0.15%	-21.70%

05-07	Nuvectis Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-08	Nuvectis Pharma's Nxp900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines	CI

Nuvectis Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07
Nuvectis Pharma's Nxp900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines	04-08
Nuvectis Pharma, Inc. Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant Arid1a-Mutated Ovarian Cancer	03-14
Nuvectis Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-05
Nuvectis Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08
Nuvectis Pharma Starts Phase 1a Trial of NXP900 in Solid Tumors	12/09/23
Nuvectis Pharma, Inc. Announces Initiation of the NXP900 Phase 1a Clinical Trial	12/09/23
Nuvectis Pharma's NXP800 Cholangiocarcinoma Treatment Candidate Gets US FDA Orphan Drug Label	17/08/23
Nuvectis Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23
Insider Buy: Nuvectis Pharma	27/07/23
Insider Buy: Nuvectis Pharma	24/07/23
Insider Buy: Nuvectis Pharma	20/07/23
Insider Buy: Nuvectis Pharma	19/07/23
Insider Buy: Nuvectis Pharma	12/07/23
Insider Buy: Nuvectis Pharma	10/07/23
Insider Buy: Nuvectis Pharma	27/06/23
Insider Buy: Nuvectis Pharma	20/06/23
Insider Buy: Nuvectis Pharma	16/06/23
Nuvectis Pharma Says US FDA Cleared Investigational New Drug Application for Oncology Drug Candidate NXP900	15/05/23
Nuvectis Pharma Inc. Announces FDA Clearance of NXP900 IND	15/05/23

No results for this search